ESPS to Host e-Compliance Management Seminars for Pharmaceutical-Related Industries.

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Nov. 30, 1999--

Innovative Seminars Address Key Internal/External Compliance

Concerns for Today's Pharmaceutical, Biotechnology and Medical

Device Companies

ESPS, Inc. (Nasdaq: ESPS), today announced that it is hosting two e-Compliance Management seminars specifically for the pharmaceutical and related industries, such as biotechnology, generics, medical devices, contract research organizations and animal health. e-Compliance or electronic compliance incorporates the use of Internet and intranet technologies to manage the assembly and publishing of business-critical regulatory compliance knowledge. Business compliance issues are complex for the various pharmaceutical-related industries, hence, these seminars are targeted to the senior regulatory, quality assurance and IT executives responsible for improving compliance-related activities within their organizations.

The dates of the sessions are December 3 at the Hyatt Regency Cambridge in Cambridge, MA and December 10 at the Renaissance Madison in Seattle, WA. Both seminars require advance registration to attend.

The e-Compliance Management seminars will discuss the robust functionality of the ESPS CoreDossier(R) software suite for the healthcare manufacturing market. Current ESPS pharmaceutical customers will present case studies, highlighting the tangible benefits and return on investment they have achieved using CoreDossier. A product demonstration also will be included.

"The paperwork required to get a new drug or medical device to market is a major challenge for healthcare manufacturing companies today and the potential exists to lose money every day a product's regulatory approval is delayed," said Robert Kuller, global director of pharmaceutical and medical device markets at ESPS.

Regulatory approval of the efficacy and safety of a product is necessary before marketing a new drug or medical device. A typical new drug application (NDA) filed with the U.S. Food and Drug Administration (FDA) can average 500,000 pages or more. In many cases, a company must rent a tractor-trailer to deliver the required three copies of the application to the FDA. "Time and money that goes towards compliance paperwork takes resources away from other research," Mr. Kuller said. "Electronic compliance gives companies an advantage over those that are still filling out thousands of pages of paperwork."

ESPS' CoreDossier(R) e-Compliance software helps companies with their business-critical compliance issues, including the NDA process, moving compliance-related submissions and reporting along more quickly for customers. CoreDossier publishes to the Internet, corporate intranets, directly to paper or to industry-specific standards in formats like HTML, XML, PDF and TIFF.

Some advantages of using the power of CoreDossier software in the healthcare manufacturing marketplace include:

- Streamlining the document assembly and publication process (i.e.,

graphs, tables, spreadsheets, maps, reports), thus, reducing

cycle times;

- Improving the quality of submissions during the assembly process,

rather than after, when corrections are more difficult;

- Improving the consistency of the entire publication (e.g. uniform

headers and footers);

- Allowing faster review internally and externally;

- Eliminating multiple file format conversion headaches;

- Accelerating dissemination of mission-critical business

compliance knowledge.

About ESPS

ESPS, Inc. is the leading developer of electronic compliance (e-Compliance) software solutions used to manage, publish and share regulatory submissions and other business compliance information. ESPS solutions address the needs of companies faced with regulatory compliance submission requirements through the application of industry expertise, advanced technology and a commitment to high-quality implementations. The ESPS CoreDossier(R) software suite has set the standard for electronic compliance management in industries, including pharmaceutical, chemical and utilities. The ESPS world headquarters is located in suburban Philadelphia, with additional offices throughout North America and in Europe. More information can be found at www.esps.com, or by reaching the Company at 800.515.ESPS (North America) or [phone] (Europe).

The statements in this news release which are not historical facts are forward-looking statements. These forward-looking statements involve risks and uncertainties that could render them materially different, including, but not limited to, the effect of fluctuations in the Company's operating results, the Company's reliance on a limited number of significant customers, the Company's reliance on the CoreDossier product family, the Company's ability to market and sell its products and services in its targeted industries, the Company's ability to expand its sales and professional services organizations, the Company's ability to manage growth, the Company's ability to attract and retain qualified personnel, the Company's reliance on relationships with service vendors, the Company's reliance on licensed technology, the Company's ability to protect its proprietary rights, potential year 2000 problems, the Company's ability to compete in the rapidly evolving electronic compliance management market, the development and growth of the electronic compliance management market, the Company's ability to respond to changes in the electronic compliance management market, and other risks detailed in its Securities and Exchange Commission filings, including the Registration Statement on Form S-1.

CoreDossier is a registered trademark of ESPS, Inc.